The changing face of Clostridium difficile: what treatment options remain?
- PMID: 18042108
- DOI: 10.1111/j.1572-0241.2007.01533.x
The changing face of Clostridium difficile: what treatment options remain?
Erratum in
- Am J Gastroenterol. 2008 Feb;103(2):502. Dosage error in article text
Abstract
In this issue of the Journal, an article by Pepin et al. documents the shifting sands of the modern-day Clostridium difficile epidemic as seen in Quebec. Pepin and coauthors' observation that the superior activity of vancomycin over metronidazole has been lost since the emergence there of the hypervirulent strain NAP1/027 in 2003 has implications for the future treatment of C. difficile-associated diarrhea (CDAD). This editorial explores these, particularly in complicated cases and high-risk populations.
Comment on
-
Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.Am J Gastroenterol. 2007 Dec;102(12):2781-8. doi: 10.1111/j.1572-0241.2007.01539.x. Epub 2007 Sep 26. Am J Gastroenterol. 2007. PMID: 17900327
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
